Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T86734
(Former ID: TTDI02002)
|
|||||
Target Name |
Glutaminase (GLS)
|
|||||
Synonyms |
L-glutamine amidohydrolase; Glutaminase, mitochondrial; GLS
Click to Show/Hide
|
|||||
Gene Name |
GLS; GLS2
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 4 Target-related Diseases | + | ||||
1 | Breast cancer [ICD-11: 2C60-2C6Y] | |||||
2 | Renal cell carcinoma [ICD-11: 2C90] | |||||
3 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
4 | Leukaemia [ICD-11: 2A60-2B33] | |||||
Function |
Plays a role in maintaining acid-base homeostasis. Regulates the levels of the neurotransmitter glutamate in the brain. Isoform 2 lacks catalytic activity. Catalyzes the first reaction in the primary pathway for the renal catabolism of glutamine.
Click to Show/Hide
|
|||||
BioChemical Class |
Carbon-nitrogen hydrolase
|
|||||
UniProt ID | ||||||
Sequence |
MMRLRGSGMLRDLLLRSPAGVSATLRRAQPLVTLCRRPRGGGRPAAGPAAAARLHPWWGG
GGWPAEPLARGLSSSPSEILQELGKGSTHPQPGVSPPAAPAAPGPKDGPGETDAFGNSEG KELVASGENKIKQGLLPSLEDLLFYTIAEGQEKIPVHKFITALKSTGLRTSDPRLKECMD MLRLTLQTTSDGVMLDKDLFKKCVQSNIVLLTQAFRRKFVIPDFMSFTSHIDELYESAKK QSGGKVADYIPQLAKFSPDLWGVSVCTVDGQRHSTGDTKVPFCLQSCVKPLKYAIAVNDL GTEYVHRYVGKEPSGLRFNKLFLNEDDKPHNPMVNAGAIVVTSLIKQGVNNAEKFDYVMQ FLNKMAGNEYVGFSNATFQSERESGDRNFAIGYYLKEKKCFPEGTDMVGILDFYFQLCSI EVTCESASVMAATLANGGFCPITGERVLSPEAVRNTLSLMHSCGMYDFSGQFAFHVGLPA KSGVAGGILLVVPNVMGMMCWSPPLDKMGNSVKGIHFCHDLVSLCNFHNYDNLRHFAKKL DPRREGGDQRVKSVINLLFAAYTGDVSALRRFALSAMDMEQRDYDSRTALHVAAAEGHVE VVKFLLEACKVNPFPKDRWNNTPMDEALHFGHHDVFKILQEYQVQYTPQGDSDNGKENQT VHKNLDGLL Click to Show/Hide
|
|||||
HIT2.0 ID | T81OKW |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | CB-839 | Drug Info | Phase 2 | Breast cancer | [2] | |
Mode of Action | [+] 2 Modes of Action | + | ||||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | CB-839 | Drug Info | [1] | |||
Inhibitor | [+] 12 Inhibitor drugs | + | ||||
1 | PMID30273516-Compound-1 | Drug Info | [3] | |||
2 | PMID30273516-Compound-12 | Drug Info | [3] | |||
3 | PMID30273516-Compound-13 | Drug Info | [3] | |||
4 | PMID30273516-Compound-14 | Drug Info | [3] | |||
5 | PMID30273516-Compound-15 | Drug Info | [3] | |||
6 | PMID30273516-Compound-22a | Drug Info | [3] | |||
7 | PMID30273516-Compound-22b | Drug Info | [3] | |||
8 | PMID30273516-Compound-37 | Drug Info | [3] | |||
9 | PMID30273516-Compound-38 | Drug Info | [3] | |||
10 | PMID30273516-Compound-39 | Drug Info | [3] | |||
11 | PMID30273516-Compound-40 | Drug Info | [3] | |||
12 | PMID30273516-Compound-41 | Drug Info | [3] |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating microRNAs |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014 Apr;13(4):890-901. | |||||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 3 | Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.